Skip to main content

Day: June 27, 2023

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks and stable disease for over 70 weeks as a third-line treatment in a patient with metastatic melanomaMDNA11 clinical update is anticipated during calendar Q3 2023, for all dose escalation patients including high dose cohorts five and six including outcomes from safety review committee; conference call to be held in conjunction with clinical updatePhase 2 ABILITY study’s single agent dose expansion portion is expected to commence in calendar Q3 2023$33.6 million in cash and cash equivalents as of March 31, 2023 expected to provide runway through key milestones of the ABILITY study and through calendar Q3 2024TORONTO and HOUSTON, June 27, 2023 (GLOBE NEWSWIRE) — Medicenna...

Continue reading

Aemetis RNG Production Exceeds Plan by 20% During Q2 2023

Seven dairy digesters, 40-mile biogas pipeline, centralized Biogas-to-RNG facility, and utility pipeline interconnection are operating 24×7 to deliver RNG for the displacement of petroleum-based fuels in trucks, buses, and cars CUPERTINO, CA, June 27, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas (RNG) and renewable fuels company focused on negative carbon intensity products, announced today that its Aemetis Biogas subsidiary is operating the Central Dairy Project production facilities 24 hours per day, seven days per week, and exceeded the RNG production plan by approximately 20% during Q2 2023. “Production rates at our dairy digesters are notably higher than our original projections,” stated Andy Foster, President of Aemetis Biogas. “Our biogas pipeline, biogas-to-RNG production...

Continue reading

LiveOne Reports Fiscal Year 2023 Revenue of $99.6M and Record Adjusted EBITDA* of $10.9M, a $24.4M Improvement Year-Over-Year

Audio Division Revenue of $86.8M and Adjusted EBITDA* of $18.2M for Fiscal Year 2023, a 289% Increase Year-Over-Year Raises Fiscal Year 2024 Revenue Guidance for Audio Division to $100M – to $110M and Adjusted EBITDA* to $18M – $21M Audio Division Q4 Fiscal 2023 Revenue of $22.9M and Adjusted EBITDA* of $4.5M versus $2.4M in Q4 Fiscal 2022, an 89% Increase Raises Company Guidance for Fiscal Year 2024 Revenue of $122M – $130M and Adjusted EBITDA* of $12M – $16M LiveOne’s PodcastOne Expects to Deliver a Record-Breaking Q1 Fiscal 2024 of Over $10.5M in Revenue and Fiscal Year 2024 Revenue Between $40M – $45M PodcastOne’s S-1 Registration Statement Declared Effective by the SEC Repaid $3 million of PodcastOne Debt Increased PodcastOne Special Dividend from 12% to ~ 19% Record Growth of 612K+ New Paid Members – a...

Continue reading

Talenom acquires a Spanish accounting company Aditio Gestion

Talenom Plc, Press release 27 June 2023 at 15:00 EEST Talenom acquires a Spanish accounting company Aditio Gestion Talenom Plc has agreed to acquire the entire share capital of Aditio Gestion S.l., an accounting company operating in Asturias and Madrid, Spain. The acquired company will be transferred to Talenom on 27 June 2023. Aditio Gestion provides accounting, tax and other advisory services mainly to SMEs in the region. The net sales transferred to Talenom from the acquired company is some EUR 1.7 million annually. The company employs a total of 30 persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company...

Continue reading

Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. “Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleased that he has agreed to join,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. “As our momentum continues to accelerate,...

Continue reading

Gentex Foundation Awards First Recipients of College Scholarship to Support Women in Stem

Gentex Scholarship Winners The Gentex Foundation has named Madelyn Rynsburger and Paige Lampen the first recipients of the Amanda Clark Scholarship, a new program announced in October of last year, to support female high school seniors pursuing a degree in science, technology, engineering, or math (STEM). Left to right: Ally Clark (Amanda Clark’s Daughter), Paige Lampen (Scholarship Winner), Madelyn Rynsburger (Scholarship Winner), Seth Bushouse (Gentex Sr. Dir. Human Resources)ZEELAND, Mich., June 27, 2023 (GLOBE NEWSWIRE) — The Gentex Foundation has selected the first recipients of the Amanda Clark Scholarship, a new program announced in October of last year, to support female high school seniors pursuing a degree in science, technology, engineering, or math (STEM). The scholarship committee selected two winners this year:...

Continue reading

Actelis Selected to Upgrade HVAC Networking Solution for United States Military Under Base Modernization Initiative

International Engineering Firm, Jacobs, Partners with Actelis Utilizing its Cyber-Hardened, Rapid Deployment Hybrid Fiber-Copper Networking Solution To Quickly Complete Upgrade Project FREMONT, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ:ASNS) (“Actelis” or the “Company”) a market leader in cyber-hardened, rapid deployment networking solutions for wide area IoT applications, today announced that its hybrid fiber-copper networking solution has been selected for installation by the United States military to enable and extend connectivity for Heating, Ventilation, and Air Conditioning (HVAC) system monitoring and control. The project is being deployed in conjunction with Actelis integration partner, Jacobs, and will replace the client’s existing 3rd party connectivity solution. HVAC monitoring systems include...

Continue reading

TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project

ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments (A2PEX) Grant Program. A2PEX is a five-year project led by the Florida Institute for Human and Machine Cognition (IHMC) that includes internationally-recognized leaders in wearable technologies from industry and academia. The goal of A2PEX is to build a wearable system to sense, assess and augment cognitive performance in operational environments. Sensors developed by A2PEX partners will develop electrophysiological and biomarker...

Continue reading

First Wave BioPharma Strengthens Intellectual Property Estate

USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods of use claims involving new enteric formulation and malabsorption indication BOCA RATON, Fla., June 27, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced the publication of two patent applications for composition of matter and methods of use claims governing the Company’s enhanced enteric microgranule delivery formulation of adrulipase. The two applications were published by both the United States Patent and Trademark Office (USPTO) and the International Bureau of the World International Patent Organization (WIPO)...

Continue reading

GXO Expands Partnership with Abercombie & Fitch to the U.K.

Following successful operations in the U.S., GXO to handle 100% of Abercrombie & Fitch’s ecommerce operations, including returns, in the U.K. GREENWICH, Conn. and LONDON, U.K., June 27, 2023 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, announced today that it has expanded its partnership with leading global specialty apparel and accessories retailer Abercrombie & Fitch Co. (A&F Co.), managing its ecommerce fulfillment and returns in the U.K. from its dedicated, newly refurbished 170,000-square-foot facility outside London. The expansion follows the success of GXO’s partnership with A&F Co. in the U.S. where the company operates a high-tech distribution centre featuring advanced automation and goods-to-person robotics, intelligent analytics and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.